Krista Menard

BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR

Zheng Yang, G. Trainor, F. Lee, 2009, Molecular Cancer Therapeutics.

Preclinical efficacy spectrum and pharmacokinetics of ixabepilone

F. Lee, C. Fairchild, R. Kramer, 2008, Cancer Chemotherapy and Pharmacology.

Development of BET inhibitors as potential treatments for cancer: A search for structural diversity.

M. D. Hill, J. Tokarski, S. Sheriff, 2021, Bioorganic & medicinal chemistry letters.

Targeting DDR2 enhances tumor response to anti–PD-1 immunotherapy

Robert T. Jones, J. Costello, N. Agarwal, 2019, Science Advances.

Discovery and Preclinical Pharmacology of an Oral Bromodomain and Extra-Terminal (BET) Inhibitor Using Scaffold-Hopping and Structure-Guided Drug Design.

Vijay T. Ahuja, Derek J. Norris, J. Tokarski, 2021, Journal of medicinal chemistry.

Discovery of Clinical Candidate BMS-906024: A Potent Pan-Notch Inhibitor for the Treatment of Leukemia and Solid Tumors.

Derek J. Norris, D. Shen, G. Trainor, 2015, ACS medicinal chemistry letters.

Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development.

G. Trainor, A. Mathur, D. Langley, 2009, Journal of medicinal chemistry.

BMS-871: a novel orally active pan-Notch inhibitor as an anticancer agent.

Derek J. Norris, D. Shen, G. Trainor, 2015, Bioorganic & medicinal chemistry letters.